Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
5.84
+0.59 (11.24%)
At close: May 18, 2026, 4:00 PM EDT
5.80
-0.04 (-0.68%)
Pre-market: May 19, 2026, 7:37 AM EDT
Plus Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Plus Therapeutics stock has a consensus rating of "Buy" and an average price target of $38. The average 1-year stock price forecast is 550.68% higher than the current stock price, while the lowest is $12 (+105.48%) and the highest is $65 (+1,013.01%).
Price Target: $38 (+550.68%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 9, 2026.
Analyst Ratings
The average analyst rating for Plus Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $475 → $65 | Strong Buy | Maintains | $475 → $65 | +1,013.01% | Apr 9, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 31, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $75 | Strong Buy | Maintains | $75 | +1,184.25% | Mar 19, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $25 | Strong Buy | Maintains | $50 → $25 | +328.08% | Jan 23, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $125 → $100 | Strong Buy | Maintains | $125 → $100 | +1,612.33% | Jan 22, 2026 |
Financial Forecast
Revenue This Year
5.90M
from 5.21M
Increased by 13.20%
Revenue Next Year
21.33M
from 5.90M
Increased by 261.48%
EPS This Year
-3.66
from -7.25
EPS Next Year
-2.28
from -3.66
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 11.9M | 29.4M | ||||||
| Avg | 5.9M | 21.3M | ||||||
| Low | 3.9M | 9.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 127.6% | 398.2% | ||||||
| Avg | 13.2% | 261.5% | ||||||
| Low | -24.8% | 66.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | -2.89 | -1.84 | ||||
| Avg | -3.66 | -2.28 | ||||
| Low | -4.53 | -2.64 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.